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Abstract
Aim: To estimate and examine hospitalisation costs of Type 1 and Type 2 diabe-
tes in an Irish public hospital.
Methods: A retrospective audit of hospital inpatient admissions over a 5- year 
period was undertaken, and a wide range of admission- related data were col-
lected for a sample of 7,548 admissions. Hospitalisations were costed using the 
diagnosis- related group methodology. A series of descriptive, univariate and mul-
tivariate regression analyses were undertaken.
Results: The mean hospitalisation cost for Type 1 diabetes was €4,027 and for 
Type 2 diabetes was €5,026 per admission. Sex, admission type and length of stay 
were significantly associated with hospitalisation costs for admissions with a pri-
mary diagnosis of Type 1 diabetes. Age, admission type, diagnosis status, compli-
cations status, discharge destination, length of stay and year were significantly 
associated with hospitalisation costs for admissions with a primary diagnosis of 
Type 2 diabetes. Length of stay was associated with higher mean costs, with each 
additional day increasing Type 1 diabetes costs by €260 (p = 0.001) and Type 2 
diabetes by €216 (p < 0.001). Unscheduled admissions were associated with sig-
nificantly lower costs than elective admissions; €1,578 (p = 0.035) lower for Type 
1 diabetes and €2,108 (p < 0.001) lower for Type 2 diabetes.
Conclusions: This study presents estimates of the costs of diabetes care in the 
Irish public hospital system and identifies the factors which influence costs for 
Type 1 and Type 2 diabetes. These findings may be of interest to patients, the 
public, researchers and those with influence over diabetes policy and practice in 
Ireland and internationally.
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1  |  INTRODUCTION
Diabetes and its complications cause substantial eco-
nomic impacts for those living with the condition and 
their families, for health systems and for economies 
through, for example, direct medical and healthcare costs, 
and indirect costs, such as the loss of work, wages and pro-
ductivity.1 There is a need to better understand the nature 
of the economic burden of diabetes on healthcare systems 
to better inform those charged with directing future pol-
icy and practice. The projected growth in diabetes poses 
a further significant risk to the operation and financing 
of the healthcare systems and requires an evidence base 
to inform the necessary policy response. A better under-
standing of the nature and drivers of diabetes costs may 
not only highlight the potential impact of rising preva-
lence levels but also form the economic basis for invest-
ment in preventive and clinical management strategies for 
Type 1 and Type 2 diabetes. Within this context, the role 
of hospital care is a key consideration, as it constitutes the 
major component of the healthcare burden of diabetes, 
and therefore, it has the greatest potential to benefit from 
the cost savings attributable to improvements in diabetes 
prevention and clinical management.
Limited evidence is available on the economics of 
diabetes care in Ireland. In the case of the Irish health-
care system, the estimated cost of managing diabe-
tes is 12– 14% (approximately €2billion) of the annual 
health budget.2 Adopting a cost of illness approach, the 
CODEIRE study3 demonstrated Type 2 diabetes to be a 
costly disease in Ireland in 2006, with annual total di-
rect costs (hospitalisations, ambulatory and drug costs) 
estimated at €580 million for both diagnosed and undi-
agnosed diabetes. Notably, the study stated that hospi-
talisations were the main driver of costs, accounting for 
almost half of the overall cost estimate, which was pri-
marily due to diabetes- related complications. In a more 
recent study based on a cross- sectional analysis of The 
Irish LongituDinal Study on Ageing (TILDA),4 the incre-
mental cost of the additional service use attributable to 
diabetes was estimated to be €89 million annually, with 
hospital admission accounting for 67% of these costs.5 
Importantly, these estimates were based on self- reported 
service use by study participants. Indeed, this reflects 
a historical paucity in the availability of healthcare re-
source use and cost data for Ireland, and the pragmatic 
approaches that researchers have had to take to address 
this problem. Notwithstanding this limited economic 
evidence base for Ireland, a particular area of concern 
given the projected growth in diabetes care is that of the 
already resource- constrained public hospital system. 
Moreover, with recent improvements in hospitalisation 
data availability in Ireland, there an onus on researchers 
to use these data to provide better evidence relating to 
hospitalisation costs, and in doing so, to better inform 
healthcare decision making process. In this paper, hos-
pitalisation data obtained from an Irish public hospital, 
and costed using the diagnosis- related group methodol-
ogy, was used to estimate and examine the costs of Type 
1 diabetes and Type 2 diabetes in Ireland. The implica-
tions of the Covid- 19 pandemic for diabetes care in pub-
lic hospital systems is an important consideration as the 
impacts of delaying necessary hospital- based diabetes 
treatment because of Covid- 19, will likely increase the 
future burden on public hospitals as they attempt to con-
tinue to meet ongoing healthcare needs in the future.
2  |  RESEARCH DESIGN AND 
METHODS
2.1 | Data sources and sample 
characteristics
A retrospective audit of diabetes- related hospital ad-
missions for the period 2013– 2017 inclusively, was un-
dertaken for an Irish public hospital in the west of the 
country. Ethical approval for the study was obtained from 
the hospital- based Clinical Research Ethics Committee on 
11 June 2019 following which a request was made to the 
Hospital Inpatient Enquiry (HIPE) Department, the na-
tional agency responsible for public hospital data records 
in Ireland. Diabetes- related admissions in HIPE were 
identified using the International Statistical Classification 
of Diseases and Related Health Problems, 10th Revision 
(ICD- 10 V. 8.0) categorisation and based on HIPE’s qual-
ity reports (Appendix A).
Novelty statement
• Diabetes and its complications cause substan-
tial economic impacts for those living with the 
condition and their families, for health systems 
and for economies. Our findings highlight the 
average costs of care for Type 1 and Type 2 dia-
betes, and thereby point to the potential cost 
savings that may be achievable through invest-
ment in effective diabetes prevention and clini-
cal management strategies which reduce rates 
of hospitalisations. These data form part of the 
economic rationale to support international 
policy recommendations and investment in di-
abetes prevention and clinical management in 
primary and community care.
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Only those with a diabetes- related admission on their 
record were included in this data set, which comprised of 
7,548 single hospital admissions and up to 16 diagnostic 
fields and five procedure fields. Data extracted included 
admission and discharge dates (i.e. length of hospital 
stay in days), primary diagnosis on hospital admission, 
diabetes complications ((no complications, one compli-
cation, two complications, three or more complications 
(Appendix A)), age, sex, admission type (elective and un-
scheduled), discharge destination (self, residence/home, 
nursing home, emergency and nonemergency transfer to 
other acute hospital, psychiatric hospital and decreased), 
insurance type (public or private) and Diagnoses Related 
Group (DRG) category and cost rate. As outlined in 
Table 1, of the sample, 427 (6%) were diagnosed with Type 
1 diabetes and 7,121 (94%) with Type 2 diabetes. The sam-
ple was aged between 21 and 106  years (75  ±  14); with 
4,473 men (59%) and 3,075 women (41%) included in this 
cohort.
2.2 | Cost analysis
Public hospitalisations in Ireland are categorised into 
DRGs, that are associated with cost and reimbursement 
rates using a method based on the Australian Diagnosis 
Related Groups (ARDRG) system.6 The costs per DRG, 
which were presented in Euros in 2017 prices, and ob-
tained from the Activity Based Funding price list for 
Ireland7 were applied to estimate the cost of each hospi-
talisation in the data set.
2.3 | Statistical analysis
A series of descriptive, univariate and multivariate regres-
sion analyses, using a generalised linear model (GLM) 
technique, were undertaken. Means, medians, standard 
deviations and interquartile ranges were estimated to sum-
marise hospitalisation costs for Type 1 diabetes and Type 
2 diabetes. The univariate analysis consisted of independ-
ent t- tests, analysis of variance (ANOVA) for continuous 
variables and χ2 tests for categorical variables to examine 
associations between participants and treatment- related 
factors, admissions and costs for Type 1 and Type 2 diabe-
tes. A GLM regression assuming a distribution informed 
by a modified park test, and a log link function informed 
by a Pearson correlation test, a Pregibon link test and a 
Modified Hosmer and Lemeshow test, was adopted for the 
cost regression analysis. This approach has been shown to 
be appropriate for the analysis of cost data, which is often 
complicated in nature.8,9 Separate cost regression models 
were estimated for Type 1 diabetes and Type 2 diabetes; 
in both cases, the models were estimated controlling for 
sex, age, admission type, primary diagnosis status, com-
plications status, health insurance status, discharge des-
tination and length of stay in days and year. Statistical 
significance was explored at the 0.05 level, model fit by 
the Akaike information criterion (AIC), and all analyses 
performed using SPSS version 26.0 software10 and Stata 
version 15.0 software.11
3  |  RESULTS
Summary statistics on the characteristics of study partici-
pants and a comparison for those with Type 1 and Type 
2 diabetes are provided in Table 1. It is notable that sta-
tistically significant differences exist with respect to age, 
sex, primary diagnosis of diabetes on hospital admission, 
complications, discharge destination, discharge year and 
length of stay in days (Table S1) between Type 1 and Type 
2 diabetes. For example, Type 2 diabetes admissions were 
more likely to be men, have a primary diagnosis on hos-
pital admission other than diabetes, experience diabetes- 
related complications and have a longer length of hospital 
stay.
Table  2 (and Table  S2) presents the results for the 
summary statistics for single hospitalisation costs and 
the univariate analysis. The mean hospitalisation cost 
for Type 1 diabetes was €4,027 and for Type 2 diabetes 
was €5,026 per admission. In the case of Type 1 diabe-
tes, mean inpatient costs were higher for men, and for 
those aged 75 years and over, relative to those in younger 
age groups. For Type 2 diabetes, older age was associ-
ated with higher inpatient costs, with costs for those 
aged 75 years and over, generally higher than those for 
younger age groups. In addition, Type 2 diabetes costs 
were higher for elective admissions among those with 
diabetes complications and where diabetes was not their 
primary diagnosis on hospital admission. In respect of 
discharge destination, costs were found to vary signifi-
cantly among those with Type 1 and Type 2 diabetes. For 
example, discharges to hospice and nursing care homes 
showed higher costs for those participants with Type 
2 diabetes with significantly higher costs observed for 
those individuals who died while in hospital. Notably, 
costs of Type 2 diabetes appeared to be decreasing mar-
ginally from 2013 to 2017.
The results for the GLM analyses of hospitalisation 
costs are presented in Table 3 and are summarised below. 
In both cases, a GLM regression assuming an inverse 
Gaussian distribution and a 1.5 power link function was 
the preferred approach. The results for the following al-
ternative model specifications are presented in the sup-
plementary materials (Tables S3– S5): (S3) Family: inverse 
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T A B L E  1  Sample characteristics
Variable
Total sample  
(n = 7548)
Type 1 diabetes 
(n = 427)
Type 2 diabetes 
(n = 7121) p- value
Sex
Men 4,473 (59) 228 (53) 4,245 (60)









 < 30 years 114 (1.5) 93 (22) 21 (0.3) <0.001
30– 44 years 203 (2.7) 108 (25) 95 (1.3)
45– 59 years 599 (7.9) 93 (22) 506 (7.1)
60– 74 years 2,053 (27) 61 (14) 1,992 (28)
75+ years 4,578 (61) 71 (17) 4,507 (63)
Admission type
Elective 580 (7.7) 28 (6.6) 552 (7.8) 0.368
Unscheduled 6,968 (92) 399 (93) 6,569 (92)
Primary diagnosis on hospital admission
Not diabetes 6,941 (92) 242 (57) 6,699 (94) <0.001
Diabetes 607 (8.0) 185 (43) 422 (5.9)
Complications
No diabetes complications 3,799 (50) 152 (36) 3,647 (51) <0.001
1 diabetes complication 3,162 (42) 223 (52) 2,939 (41)
2 diabetes complications 455 (6.0) 35 (8.2) 420 (6.0)
3 or more complications 132 (1.7) 17 (4.0) 115 (1.6)
Insurance
Public 7,026 (93) 388 (91) 6,638 (93) 0.063
Private 522 (6.9) 39 (8.9) 483 (6.8)
Discharge destination
Self- discharged 52 (0.7) 11 (2.6) 41 (0.6) <0.001
Residence (return home) 5,937 (79) 390 (91) 5,547 (78)
Nursing/care home 902 (12) 15 (3.5) 887 (12)
Emergency transfer 325 (4.3) 9 (1.9) 316 (4.4)
Psychiatric hospital 45 (0.6) 0 (0.0) 45 (0.6)
Hospice 47 (0.6) 0 (0.0) 47 (0.7)
Died 240 (3.2) 2 (0.5) 238 (3.3)
Discharge year
2013 1177 (16) 80 (19) 1097 (15.4) <0.001
2014 1267 (17) 103 (24) 1164 (16)
2015 1582 (21) 74 (17) 1508 (21)
2016 1679 (22) 84 (20) 1595 (22.4)
2017 1843 (24) 86 (20) 1757 (25)







Note: Statistical analysis consisted of t- test for continuous variables and χ2 tests for categorical variables. Continuous data is displayed as mean ± SD, median 
(quartile 1, quartile 3); categorical data are reported as n (%).
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Gaussian; Link: Identity; (S4) Family: Gamma; Link: Log; 
(S5) Family: Gaussian; Link: Identity.
Sex, admission type and length of stay were signifi-
cantly associated with costs for admissions with a primary 
diagnosis of Type 1 diabetes. Women's admissions were 
less costly by €866 (p  <  0.001) than men's admissions. 
Admissions with a primary diagnosis of diabetes were as-
sociated with higher costs of €654 (p = 0.007) relative to 
T A B L E  2  Mean ± SD of inpatient costs (€) for Type 1 and Type 2 diabetes
Variable
Inpatient costs €
Type 1 diabetes p- value
Inpatient costs €
Type 2 diabetes p- value
Full sample 4027 ± 3604 5026 ± 5674 <0.001
Sex
Men 4464 ± 4319 0.007 4983 ± 5498 0.436
Women 3528 ± 2456 5081 ± 5924
Age
 < 30 years 3529 ± 2117 0.004 3483 ± 2988 <0.001
30– 44 years 3162 ± 1637 3738 ± 2679
45– 59 years 4667 ± 5974 4935 ± 7822
60– 74 years 4341 ± 3102 4709 ± 5779
75+ years 4884 ± 3276 5211 ± 5379
Admission type
Elective 5079 ± 2647 0.110 6570 ± 6078 <0.001
Unscheduled 3954 ± 3649 4896 ± 5619
Primary diagnosis on hospital admission
Not primary diagnosis 3995 ± 3200 0.837 5057 ± 5790 0.003
Primary diagnosis 4070 ± 4074 4533 ± 3274
complications
No diabetes complications 3628 ± 2355 0.350 4500 ± 4689 <0.001
1 diabetes complication 4183 ± 4401 5472 ± 6340
2 diabetes complications 4543 ± 2502 5954 ± 5798
3 or more complications 4492 ± 2841 6911 ± 11273
Insurance
Public 4021 ± 3725 0.904 4988 ± 5438 0.145
Private 4094 ± 2000 5545 ± 8246
Discharge destination
Self- discharged 4151 ± 3824  < 0.001 4100 (3214) <0.001
Residence (return home) 3864 ± 3457 4528 (4317)
Nursing/care home 5914 ± 2340 6165 (6551)
Emergency transfer 4542 ± 3471 5640 (9075)
Psychiatric hospital n/a 6436 (8104)
Hospice n/a 6525 (2881)
Died 18877 ± 7607 11169 (13977)
Discharge year





Note: Statistical analysis consisted of independent t- tests for binary predictors and ANOVA those categorical predictors with more than two levels. As both 
t- test and ANOVA involve comparison of group means, results for costs are displayed as mean ± SD.
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an alternative diagnosis. Unscheduled admissions were 
associated with lower costs of €1578 (p = 0.035) relative 
to elective admissions. Length of stay was associated with 
higher mean costs, with each additional day increasing 
costs by €260 (p = 0.001). Admissions for women aged be-
tween 30 and 44 years were less costly than those aged less 
T A B L E  3  Marginal effects and standard errors for variables associated with in- patient diabetes costs, estimated using generalised linear 
models with an inverse Gaussian distribution and a 1.5 power link function
Variable
Type 1 diabetes Type 2 diabetes
inpatient costs €
marginal effects (standard 
errors) p- value
inpatient costs €  
marginal effects  
(standard errors) p- value
Sex
Men (reference category (Ref))
Women −866 (205)  < 0.001 62 (52) 0.232
Age
 < 30 years (Ref)
30– 44 years −449 (239) 0.060 121 (212) 0.568
45– 59 years 86 (341) 0.800 452 (199) 0.023
60– 74 years 54 (337) 0.872 697 (192)  < 0.001
75+ years 12 (322) 0.970 855 (191)  < 0.001
Admission type
Elective (Ref)
Unscheduled −1578 (748) 0.035 −2108 (224)  < 0.001
Primary diagnosis
Not primary diagnosis (Ref)
Primary diagnosis 654 (242) 0.007 330 (133) 0.014
Complications
No diabetes complications (Ref)
1 diabetes complication 165 (218) 0.449 536 (68)  < 0.001
2 diabetes complications 390 (563) 0.489 719 (177)  < 0.001
3 or more complications −216 (510) 0.672 848 (374) 0.023
Insurance
Public (Ref)
Private 416 (415) 0.317 176 (118) 0.134
Discharge destination
Self- discharged −20 (512) 0.969 −315 (194) 0.104
Residence (return home) (Ref)
Nursing/care home 1307 (1307) 0.289 633 (133)  < 0.001
Emergency transfer −1030 (1233) 0.289 533 (197) 0.007
Psychiatric hospital n/a n/a 766 (488) 0.117
Hospice n/a n/a 1946 (902) 0.031
Died 22968 (37891) 0.544 6795 (1050)  < 0.001
Length of stay (Days) 260 (48)  < 0.001 216 (9)  < 0.001
Year
2013 (Ref)
2014 38 (297) 0.897 99 (101) 0.329
2015 85 (285) 0.766 51 (91) 0.572
2016 120 (220) 0.584 449 (98)  < 0.001
2017 −171 (256) 0.505 191 (93) 0.041
Note: Abbreviation: Ref, reference category; IG, inverse Gaussian; AIC, Akaike Information Criterion.
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than 30 years while discharge destination, and, if a patient 
died in hospital were associated with a cost increase rel-
ative to the reference category of residence, however, no 
association was observed in the multivariable analysis. In 
2017, costs decreased per admission relative to previous 
years; however, these differences were also not found to 
be significant.
Age, admission type, diagnosis status, complications 
status, discharge destination, length of stay and year 
were significantly associated with costs for admissions 
with a primary diagnosis of Type 2 diabetes. Relative to 
those aged under 30 years, older age cohorts of 45– 59, 
60– 74 and 75 and over were associated with additional 
costs of €452 (p  =  0.023), €697 (p  <  0.001), and €855 
(p < 0.001) respectively. Admissions with a primary di-
agnosis of diabetes were associated wither higher costs 
of €330 (p = 0.014). Unscheduled admissions were as-
sociated with lower costs of €2,108 (p < 0.001) relative 
to elective admissions. Complications were associated 
with higher costs, with one, two and three or more 
complications associated with additional costs of €536 
(p < 0.001), €719 (p < 0.001), and €848 (p = 0.023), re-
spectively. Discharge destination for Type 2 diabetes 
were higher for those discharged to further care and 
those who died, relative to those discharged home. 
Length of stay was associated with higher mean inpa-
tient costs, with each additional day increasing costs by 
€216 (p  <  0.001). Notably, year was statistically signif-
icant, with 2016 and 2017 differing from the reference 
year of 2013.
4  |  DISCUSSION
Given the significant burden that diabetes places on 
healthcare systems in Ireland and internationally, and 
the role that hospital care plays in this context, this study 
estimated and examined the costs of Type 1 and Type 2 
diabetes in an Irish public hospital setting. Considering 
projected increasing prevalence levels and competing 
calls for investment on already resource constrained 
health budgets, our findings highlight the average costs of 
care for Type 1 and Type 2 diabetes, and thereby point to 
the potential cost savings that may be achievable through 
investment in effective diabetes prevention and clinical 
management strategies, which reduce rates of hospitalisa-
tions. That said, evidence on the clinical and cost effec-
tiveness of such interventions would be required to inform 
decisions on their reimbursement and implementation in 
clinical practice.
In this study, the factors associated with variations in 
hospitalisation costs were also considered. Although some 
factors are unlikely to be changed by policy intervention, 
length of hospital stay and risk factors for complications 
of diabetes are certainly modifiable. An increase in costs 
up to €6,911 was associated with Type 2 diabetes with 
complications and substantiates the investigation by 
O’Neill et al.5 that Type 2 diabetes hospitalisations due to 
diabetes- related complications are a key driver of costs. 
Each additional day in hospital increases approximately 
3 percentage points to basic costs for those with Type 1 
diabetes and 2 percentage points for those with Type 2 
diabetes. This is a significant cost driver considering the 
unwarranted extended length of hospital stay for those 
with diabetes.12 Length of stay for those transitioning to 
a nursing home is up to 14 days so a decrease here could 
lessen costs, but it is unclear from the data whether this 
pertains to the patient's illness or if awaiting suitable 
accommodation.
More needs to be done to keep people living well 
with diabetes. Treating patients with long- term condi-
tions as close to home as possible with quality care from 
a dedicated team of experienced professionals could be 
a more efficient system in the management of diabetes 
and prevention of its complications. New developments 
in technology, clinical practice and the integration of 
health and social care, primary and secondary care are 
facilitating a transformation in health service provision. 
The National Model of Integrated Care for Patients with 
Type 2 Diabetes13 aims to prevent the onset of Type 2 di-
abetes and improve the delivery of diabetes care to those 
living with the condition. This is particularly important 
for our aging population who are at increased risk of co- 
morbidities, increased prevalence of long- term conditions 
and ultimately healthcare utilisation.14 Given the health-
care utilisation impacts reported here, and the projected 
increased prevalence of diabetes in the future, there is 
likely to be a reciprocal impact on healthcare costs with 
current figures demonstrating that diabetes accounts for 
up to 14% of the Irish health budget2 and costs of service 
provision estimated to be €89 million annually.5 Similar 
costs are noted in NHS England, Wales (£14billion)12 and 
Scotland (£1billion).15 Direct costs of hospital complica-
tions constitute a large cost component of managing and 
treating diabetes.16- 18 Not only does diabetes increase 
medical expenditures, but the effect grows over time with 
the condition increasing the likelihood of hospitalisation 
by two to six times.19 The costs generated in this paper cor-
respond to other national healthcare settings with compli-
cations contributing factors in increased costs and length 
of hospital stay.
This study provides estimates of inpatient hospital-
isation costs related to Type 1 and Type 2 diabetes in the 
Irish public hospital system, using the DRG costing meth-
odology. The analysis identifies the factors which influ-
ence inpatient costs for Type 1 and Type 2 diabetes and 
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provides estimates of the potential inpatient cost savings 
that could accrue to health systems through the preven-
tion and reduction of diabetes- related complications and 
admissions. Together, these findings provide additional 
weight behind the economic argument for further invest-
ment in diabetes prevention and disease management 
strategies.20,21 That is, the prevention of diabetes- related 
inpatient admissions has the potential to generate sub-
stantial savings in health budgets, and such savings could 
be reallocated to invest in diabetes prevention and disease 
management programmes. As the study is specific to the 
Irish context, it supports the economic evidence review 
of the National Clinical Guideline for adults with Type 
1 diabetes mellitus that highlights an evidential lack of 
literature that is specific to the Irish healthcare setting22 
and further embraces the National Model of Integrated 
Care for Patients with Type 2 Diabetes.13 Considering 
the projected growth in diabetes prevalence in Ireland 
and internationally, these findings should be of interest 
to patients, the public, researchers and those with influ-
ence over diabetes care policy and practice in Ireland and 
internationally.
This paper has several limitations that need to be con-
sidered. Only those admissions with a diagnosis of dia-
betes were requested for this analysis. As a result, we are 
unable to make cost comparisons with non- diabetes ad-
missions or identify several hospitalisations for the same 
patient. A further limitation of the paper is the data itself 
wherein risk factors such as previous history of conditions, 
duration of diabetes, treatments received and biomarkers 
were not available. Another possible caveat is that many 
DRG codes distinguish between conditions where another 
complication is present, for example, this data set coded 
diabetes as a secondary diagnosis where the condition 
will require treatment and monitoring during hospital 
stay. Furthermore, primary and outpatient care costs are 
likely to be significant in these populations but were not 
included. This study used data from hospital coding prac-
tice, were variations and inaccuracies may exist. Studies 
show that barriers to clinical coding quality include the 
data generated particularly at the level of documentation 
completed by healthcare providers, incomplete and un-
organised chart documentation, and lack of communica-
tion for clarification. Furthermore, clinical coding quality 
suffered because of limited resources such as staffing and 
budget, variability in the documents used for coding and 
illegibility of handwriting when coding on paper.23- 25 
Finally, although appropriate regression approaches were 
employed and the preferred models adopted, the Pregibon 
link test result for the Type 2 diabetes analysis raises ques-
tions over the link function adopted. This reflects the com-
plexity in analysing cost data and should be considered in 
the interpretation of the findings presented.
5  |  CONCLUSIONS
The estimates in this study provide a measure of the bur-
den on public hospital systems that is associated with the 
care of diabetes, the factors influencing diabetes- related 
hospitalisation costs, and the potential cost savings to 
health systems through the prevention of hospital admis-
sions. The analysis provides information that will be useful 
to future research that seeks to examine questions of the 
cost and cost effectiveness of diabetes care. In particular, 
these data form part of the economic rationale to support 
international policy recommendations and investment in 
diabetes prevention and clinical management in primary 
and community care.
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APPENDIX A
List of ICD- 10 codes used to identify Type 1 and Type 2 diabetes.
Data were received for hospital acquired diagnosis 1– 16 and procedures 1– 5 that included all diagnoses (ICD- 10- AM) 
between e10 (Type 1 diabetes mellitus) and e149 (unspecified DM without complication) and all diagnoses between e16 
(other disorders of pancreatic internal secretion) and e162 (hypoglycaemia unspecified). The complete list is provided 
below:
E10.01 Type 1 diabetes mellitus with hyperosmolarity without nonketotic hyperglycaemic- hyperosmolar coma (NKHHC)
E10.11 Type 1 diabetes mellitus with ketoacidosis, without coma
E10.29 Type 1 diabetes mellitus with other specified kidney complication
E10.31 Type 1 diabetes mellitus with background retinopathy
E10.64 Type 1 diabetes mellitus with hypoglycaemia
E10.65 Type 1 diabetes mellitus with poor control
E10.69 Type 1 diabetes mellitus with other specified complication
E10.73 Type 1 diabetes mellitus with foot ulcer due to multiple causes
E10.9 Type 1 diabetes mellitus without complication
E11.01 Type 2 diabetes mellitus with hyperosmolarity without nonketotic hyperglycaemic- hyperosmolar coma [NKHHC]
E11.02 Type 2 diabetes mellitus with hyperosmolarity with coma
E11.11 Type 2 diabetes mellitus with ketoacidosis, without coma
E11.22 Type 2 diabetes mellitus with established diabetic nephropathy
E11.29 Type 2 diabetes mellitus with other specified kidney complication
E11.33 Type 2 diabetes mellitus with proliferative retinopathy
E11.34 Type 2 diabetes mellitus with other retinopathy
E11.42 Type 2 diabetes mellitus with diabetic polyneuropathy
E11.43 Type 2 diabetes mellitus with diabetic autonomic neuropathy
E11.52 Type 2 diabetes mellitus with peripheral angiopathy, with gangrene
E11.64 Type 2 diabetes mellitus with hypoglycaemia
E11.65 Type 2 diabetes mellitus with poor control
E11.69 Type 2 diabetes mellitus with other specified complication
E11.71 Type 2 diabetes mellitus with multiple microvascular and other specified nonvascular complications
E11.72 Type 2 diabetes mellitus with features of insulin resistance
E11.73 Type 2 diabetes mellitus with foot ulcer due to multiple causes
E11.9 Type 2 diabetes mellitus without complication
E13.61 Other specified diabetes mellitus with specified diabetic musculoskeletal and connective tissue complication
E13.65 Other specified diabetes mellitus with poor control
E13.69 Other specified diabetes mellitus with other specified complication
E13.9 Other specified diabetes mellitus without complication
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APPENDIX B
Diagnosis ascertaining the presence of complications.
With complication(s) Without complication(s)




E11.02 Type 2 diabetes mellitus with
hyperosmolarity with coma
E11.11 Type 2 diabetes mellitus with
ketoacidosis, without coma
E11.22 Type 2 diabetes mellitus with
established diabetic nephropathy
E11.29 Type 2 diabetes mellitus with other
specified kidney complication
E11.33 Type 2 diabetes mellitus with
proliferative retinopathy
E11.34 Type 2 diabetes mellitus with other
retinopathy
E11.42 Type 2 diabetes mellitus with diabetic polyneuropathy
E11.43 Type 2 diabetes mellitus with
diabetic autonomic neuropathy
E11.52 Type 2 diabetes mellitus with
peripheral angiopathy, with gangrene
E11.64 Type 2 diabetes mellitus with
hypoglycaemia
E11.65 Type 2 diabetes mellitus with poor
control
E11.69 Type 2 diabetes mellitus with other
specified complication
E11.71 Type 2 diabetes mellitus with
multiple microvascular and other specified
nonvascular complications
E11.72 Type 2 diabetes mellitus with
features of insulin resistance
E11.73 Type 2 diabetes mellitus with foot
ulcer due to multiple causes
E13.61 Other specified diabetes mellitus
with specified diabetic musculoskeletal and
connective tissue complication
E13.65 Other specified diabetes mellitus
with poor control
E13.69 Other specified diabetes mellitus
with other specified complication
E10.9 Type 1 diabetes mellitus without complication
E11.9 Type 2 diabetes mellitus without complication
E13.9 Other specified diabetes mellitus without complication
